Economic evaluation of treatment with orlistat in Italian obese patients

References

• Ratner R, Goldberg R, Haffner S, et al. Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 2005;28:888–94
   Google Scholar
• Wannamethee SG, Shaper AG, Walker M. Overweight and obesity and weight change in middle aged men: impact on cardiovascular disease and diabetes. J Epidemiol Commun Health 2005;59:134–9
   Google Scholar
• Resnick HE, Valsania P, Halter JB, et al. Relation of weight gain and weight loss on subsequent diabetes risk in overweight adults. J Epidemiol Comm Health 2000;54:596–602
   PubMed Web of Science ®Google Scholar
• Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study. Diabetes Care 2004;27:155–61
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2004
   Google Scholar
• Weinstein MC, O’Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health- care evaluation: report of the ISPOR task force on good research practices – modeling studies. Value Health 2003;6: 9–17
   PubMed Web of Science ®Google Scholar
• Spiegelhalter DJ, Best NG. Bayesian approaches to multiple sources of evidence and uncertainty in complex cost- effectiveness modelling. Stat Med 2003;22:3687–709
   PubMed Web of Science ®Google Scholar
• Cooper NJ, Sutton AJ, Abrams KR. Decision analytical economic modelling within a Bayesian framework: application to prophylactic antibiotics use for caesarean section. Stat Methods Med Res 2002;11:491–512
   Google Scholar
• Cooper NJ, Sutton AJ, Abrams KR, et al. Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach. Health Econ 2004;13:203–26
   PubMed Web of Science ®Google Scholar
• Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation – a practical approach. Med Decis Making 1985;5:157–77
   PubMedGoogle Scholar
• Briggs AH. Handling uncertainty in economic evaluations and presenting the results. In: Drummond M, McGuire A, eds. Economic Evaluation in Health Care. Oxford: Oxford University Press, 2001:172–214
   Google Scholar
• ISTAT – National Institute of Statistics. Annuario Statistico Italiano 2006. Rome: ISTAT, 2006
   Google Scholar
• ISTAT – National Institute of Statistics. Stime preliminari della mortalità per causa nelle regioni italiane – Anno 2004. Rome: ISTAT, 2004
   Google Scholar
• Calle E, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999;341:1097–105
   PubMed Web of Science ®Google Scholar
• Bruno G, Merletti F, Boffetta P, et al. Impact of glycaemic control, hypertension and insulin treatment on general and cause-specific mortality: an Italian population-based cohort of Type II (non-insulin dependent) diabetes mellitus. Diabetologia 1999;42:297–301
   PubMed Web of Science ®Google Scholar
• Anderson KM, Odell PM, Wilson P, et al.. Cardiovascular disease risk profiles. Am Heart J 1991;121:293–8
   PubMed Web of Science ®Google Scholar
• L’Informatore Farmaceutico 2007 (Italian Directory of Medicines and Manufacturers). Milan: Elsevier Masson, 2007
   Google Scholar
• Jönsson B. Revealing the cost of type II diabetes in Europe. Diabetologia 2002;45:S5–12
   PubMed Web of Science ®Google Scholar
• Brown JB, Nichols GA, Glauber HS, et al. Type 2 diabetes: incremental medical care costs during the first 8 years after diagnosis. Diabetes Care 1999;22:1116–24
   PubMed Web of Science ®Google Scholar
• Ministero della Salute (Ministry of Health). Ricognizione e primo aggiornamento delle tariffe massime per la remunerazione delle prestazioni sanitarie. DM 12.09.2006; GU n° 289 del 13.12.2006
   Google Scholar
• Ministero della Salute (Ministry of Health). Statistiche sui ricoveri ospedalieri. Available at: http://www.ministerosalute.it/programmazione/sdo/ric_informazioni/sceltadrg.jsp [Last accessed 18 April 2007]
   Google Scholar
• Ministero della Salute (Ministry of Health). National Ambulatory Tariffs. Decreto del Ministro della sanità del 22 luglio 1996 «Prestazioni di assistenza specialistica ambulatoriale erogabili nell’ambito del Servizio Sanitario Nazionale e relativa tariffe»
   Google Scholar
• Piedmont Region. Regional Ambulatory Tariffs. Supplemento Ordinario n. 1 al B.U. n. 36. Deliberazione della Giunta Regionale 26 luglio 2004, n. 73–13176
   Google Scholar
• Livingston EH, Ko CY. Use of the health and activities limitation index as a measure of quality of life in obesity. Obes Res 2002;10:824–32
   PubMedGoogle Scholar
• Koopmanshap M. Coping with type II diabetes: the patient’s perspective. Diabetologia 2002;45:S18–S22
   Web of Science ®Google Scholar
• Lucioni C, Garancini MP, Massi-Benedetti M, et al. The cost of type II diabetes mellitus in Italy: a CODE-2 sub-study. Treat Endocrinol 2003;2: 121–33
   Google Scholar
• Latour-Pèrez J, Navarro-Ruiz A, Ridao-Lopez M, et al. Using clopidogrel in non-st-segment elevation acute coronary syndrome patients: a cost-utility analysis in Spain. Value Health 2004;7:52–60
   PubMed Web of Science ®Google Scholar
• ISTAT – National Institute of Statistics. Stili di vita e condizioni di salute. Indagine multiscopo sulle famiglie “Aspetti della vita quotidiana” – Anno 2003 N. 25. Rome: ISTAT, 2005
   Google Scholar
• Osservatorio Epidemiologico Cardiovascolare Italiano. Ital Heart J 2004;5:49–92S
   Google Scholar
• Briggs AH, Gray AM. Methods in health care service research – handling uncertainty in economic evaluations of healthcare interventions. Br Med J 1999;319:635–8
   PubMed Web of Science ®Google Scholar
• Caro JJ, O’Brien JA, Hollenbeak CS, et al. Economic burden and risk of cardiovascular disease and diabetes in patients with different cardiometabolic risk profiles. Value Health 2007;10:S12–20
   Web of Science ®Google Scholar
• Mora S, Yanek LR, Moy TF, et al. Interaction of body mass index and Framingham risk score in predicting incident coronary disease in families. Circulation 2005;111:1871–6
   PubMed Web of Science ®Google Scholar
• O’Meara S, Riemsma R, Shirran L, Mather L, et al. A rapid and systematic review of the clinical effectiveness and cost- effectiveness of orlistat in the management of obesity. Health Technol Assess 2001;5:1–81
   Google Scholar
• Lamotte M, Annemans L, Lefever A, et al. A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients. Diabetes Care 2002;25:303–8
   PubMed Web of Science ®Google Scholar
• Foxcroft DR, Milne R. Orlistat for the treatment of obesity: rapid review and cost-effectiveness model. Obes Rev 2000;1:121–6
   PubMedGoogle Scholar
• Maetzel A, Ruof J, Covington M, et al. Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus. Pharmacoeconomics 2003;21:501–12
   PubMed Web of Science ®Google Scholar
• Ruof J, Golay A, Berne C, et al. Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost- effectiveness as rationales for reimbursement in Sweden and Switzerland. Int J Obes 2005;29:517–23
   PubMed Web of Science ®Google Scholar
• Lacey LA, Wolf A, O’Shea D, et al. Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland. Int J Obes 2005;29:975–82
   Google Scholar
• Hertzman P. The cost effectiveness of orlistat in a 1-year weight-management programme for treating overweight and obese patients in Sweden: a treatment responder approach. Pharmacoeconomics 2005;23:1007–20
   PubMed Web of Science ®Google Scholar
• Foxcroft DR. Orlistat for the treatment of obesity: cost utility model. Obes Rev 2005;6:323–8
   PubMed Web of Science ®Google Scholar